CN110267682A - Wnt抑制剂和抗PD-1抗体分子组合的给药方案 - Google Patents

Wnt抑制剂和抗PD-1抗体分子组合的给药方案 Download PDF

Info

Publication number
CN110267682A
CN110267682A CN201880011133.5A CN201880011133A CN110267682A CN 110267682 A CN110267682 A CN 110267682A CN 201880011133 A CN201880011133 A CN 201880011133A CN 110267682 A CN110267682 A CN 110267682A
Authority
CN
China
Prior art keywords
day
cancer
pharmaceutically acceptable
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880011133.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·多布森
S·穆迪
M·E·麦克劳格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202311777725.7A priority Critical patent/CN117752784A/zh
Publication of CN110267682A publication Critical patent/CN110267682A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880011133.5A 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案 Pending CN110267682A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311777725.7A CN117752784A (zh) 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311777725.7A Division CN117752784A (zh) 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Publications (1)

Publication Number Publication Date
CN110267682A true CN110267682A (zh) 2019-09-20

Family

ID=61526841

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880011133.5A Pending CN110267682A (zh) 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案
CN202311777725.7A Pending CN117752784A (zh) 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311777725.7A Pending CN117752784A (zh) 2017-02-14 2018-02-12 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Country Status (12)

Country Link
US (2) US11406633B2 (enExample)
EP (1) EP3582811B1 (enExample)
JP (3) JP2020506159A (enExample)
KR (2) KR20190112801A (enExample)
CN (2) CN110267682A (enExample)
AU (1) AU2018221557C1 (enExample)
CA (1) CA3051989A1 (enExample)
IL (1) IL268341B2 (enExample)
MX (1) MX2019009630A (enExample)
RU (1) RU2767533C2 (enExample)
TW (1) TWI771372B (enExample)
WO (1) WO2018150312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
BR112021005525A2 (pt) * 2018-09-27 2021-06-29 Musc Foundation For Research Development combinação farmacêutica para o tratamento de câncer
US20220211715A1 (en) * 2019-05-22 2022-07-07 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369187A (zh) * 2009-03-02 2012-03-07 Irm责任有限公司 用作wnt信号调节剂的n-(杂)芳基、2-(杂)芳基取代的乙酰胺类
US20160303137A1 (en) * 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369187A (zh) * 2009-03-02 2012-03-07 Irm责任有限公司 用作wnt信号调节剂的n-(杂)芳基、2-(杂)芳基取代的乙酰胺类
US20160303137A1 (en) * 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands" *

Also Published As

Publication number Publication date
US20230063366A1 (en) 2023-03-02
EP3582811B1 (en) 2024-07-10
AU2018221557A1 (en) 2019-08-15
AU2018221557C1 (en) 2021-10-14
JP2022174157A (ja) 2022-11-22
KR20190112801A (ko) 2019-10-07
WO2018150312A1 (en) 2018-08-23
RU2019128843A3 (enExample) 2021-05-17
TWI771372B (zh) 2022-07-21
IL268341A (en) 2019-09-26
RU2019128843A (ru) 2021-03-16
JP2020506159A (ja) 2020-02-27
TW201836610A (zh) 2018-10-16
CN117752784A (zh) 2024-03-26
KR20240007717A (ko) 2024-01-16
MX2019009630A (es) 2019-11-08
JP2024133495A (ja) 2024-10-02
RU2767533C2 (ru) 2022-03-17
US20190365746A1 (en) 2019-12-05
AU2018221557B2 (en) 2021-03-11
CA3051989A1 (en) 2018-08-23
IL268341B2 (en) 2023-06-01
EP3582811A1 (en) 2019-12-25
US11406633B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
US20250223367A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
JP6663493B2 (ja) がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン
JP6588461B2 (ja) 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
JP7408396B2 (ja) 併用療法
CN107567336B (zh) 癌症的联合治疗
EP3328425B1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
EP4043492A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP2020517652A5 (enExample)
RS61228B1 (sr) Modulacija tumorske imunosti
KR20190135028A (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
CN110582303A (zh) 使用抗cd25抗体-药物缀合物的组合疗法
WO2022156727A1 (zh) 治疗肿瘤的组合物及方法
KR20230004635A (ko) Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
WO2026097102A1 (en) Methods for the treatment of cancer using microtubule targeting agents in combination with immune checkpoint modulators
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK1247848B (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190920

WD01 Invention patent application deemed withdrawn after publication